Carpp-1: Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.
Study Details
Study Description
Brief Summary
This clinical study is designed as a prospective, open-label, single arm, multicenter study to evaluate the clinical efficacy and safety of Sintilimab and Nimotuzumab in combination with chemotherapy in patients with newly diagnosed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The main endpoint is progression free survival (PFS); the secondary endpoint are objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: single arm
|
Drug: Nimotuzumab
Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks
Drug: Sintilimab
Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;
Drug: Chemotherapy drug
Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
|
Outcome Measures
Primary Outcome Measures
- Progression Free Survival [Up to 12 months]
Secondary Outcome Measures
- ORR [Up to 12 months]
objective response rate
- DCR [Up to 12 months]
disease control rate
- OS [Up to 12 months]
overall survival
Other Outcome Measures
- Biomarker [Up to 12 months]
To evaluate the relationship between tumor biomarkers (including but not limited to EGFR or PD-L1 expression, TILs, TMB, HPV status, P16 expression, etc.) and prognosis.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Voluntary and sign a consent form;
-
Age 18-75 years old, gender unlimited;
-
Histology or imaging diagnosed as R/M HNSCC, patients haven't received any anti-tumor treatment for R/M HNSCC; Including oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, paranasal sinus and nasal cavity cancer, etc.;
-
PD-L1 immunohistochemistry and EGFR immunohistochemistry should be performed on tumor tissue samples;
-
according to the efficacy evaluation criteria for solid tumors (RECIST version 1.1), at least one measurable lesion;
-
Not received any previous systemic antitumor therapy for R/M HNSCC. Subjects who had previously received adjuvant/neoadjuvant chemotherapy, or had received radical chemoradiotherapy for advanced disease, were allowed to be enrolled in this study if the interval between disease progression or recurrence and the end of the last treatment (including chemotherapy /EGFR monoclonal antibody /EGFR-TKI/ antiangiogenic agents) was beyond 6 months. Radiotherapy for individual recurrent and/or metastatic lesions cannot be ruled out.
-
ECOG PS 0-2
-
Expected survival time ≥ 3 months;
-
Enough organ function, the participants need to satisfy the following laboratory indicators: 1) nearly 14 days without the use of granulocyte colony stimulating factor, absolute neutrophil count ≥ 1.5 × 109/L; 2) Platelets ≥100×109/L in the case of no blood transfusion in the last 14 days; 3) Hemoglobin ≥9g/dL (90g/L) or≥5.6 mmol/L in the absence of blood transfusion or erythropoietin treatment within the last 14 days; 4) total bilirubin ≤1.5×upper limit of normal (ULN); 5) Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) ≤2.5×ULN, or AST/ALT≤5×ULN in subjects with liver metastasis; 6) Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 mL /min; 7) Good coagulant function; 8) Thyroid function is normal; 9) Myocardial enzyme spectrum is normal;
-
For females of reproductive age, a pregnancy test with negative results should be performed within 3 days prior to receiving the first dosing (cycle 1 day 1);
-
To avoid pregnancy, an effective contraception should used for female patients.
Exclusion Criteria:
-
squamous cell carcinoma of skin;
-
Patients with uncured malignancies other than R/M HNSCC diagnosed within 5 years prior to initial administration;
-
Participating in other clinical studies, or receiving other investigational drugs or using investigational devices within 4 weeks prior to first dosing;
-
Have received any other anti-tumor treatment for R/M HNSCC, including PD-1 inhibitor, PD-L1 inhibitor, CD137 inhibitor, EGFR monoclonal antibody, EGFR-TKI, anti-angiogenic drugs, etc.;
-
Major surgery or chemotherapy was performed within 4 weeks prior to enrollment;
-
Have received immunomodulatory drugs (including thymosin, interferon, interleukin);
-
Active autoimmune disease with systemic therapy (such as glucocorticoids or immunosuppressants) within 2 years prior to initial administration. Alternative therapy (e.g. thyroxine, insulin, etc.) is not considered systemic therapy.
-
Have received systemic glucocorticoid therapy within 7 days prior to enrollment; Note: Physiological dose of glucocorticoids (≤10 mg/ day of prednisone or equivalent drugs) is allowed.
-
Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
-
Allergic to the study drugs;
-
Have not fully recovered from toxicity and/or complications caused by any intervention prior to enrollment;
-
History of human immunodeficiency virus (HIV) infection;
-
Untreated active hepatitis B; Note: Hepatitis B patients who meet the following criteria can also be enrolled: 1) HBV DNA<1000 copies /ml (200 IU/ml) prior to enrollment; 2) anti-HBcAg(+), HBsAg (-), anti-HBsAg (-), and HBV DNA(-), prophylactic anti-HBV therapy is not required, but virus reactivation needs to be closely monitored;
-
Active HCV infection;
-
Live vaccine was given within 30 days;
-
Pregnant or lactating women;
-
Any serious or uncontrollable systemic disease;
-
Other reasons that are not suitable to participate in this study according to the researcher's judgment.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- The First Affiliated Hospital of Soochow University
- Biotech Pharmaceutical Co., Ltd.
- Cinda Biopharmaceutical (Suzhou) Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BPL-IST-H&N-20210318